Evidence for a novel, effective approach to targeting carcinoma catabolism exploiting the first-in-class, anti-cancer mitochondrial drug, CPI-613

por Guardado Rivas, Moises O., Stuart, Shawn D., Thach, Daniel, Dahan, Michael, Shorr, Robert, Zachar, Zuzana, Bingham, Paul M.
Publicado 2022